Completed PHASE1 INTERVENTIONAL 1-arm NCT00550212

Study Evaluating Oral Administrations of HKI-272 in Healthy Male Subjects

An Open-Label, Single-Dose Study of the Mass Balance and Metabolic Disposition of Orally Administered [14C]-Labeled HKI-272 in Healthy Male Subjects

Sponsor: Puma Biotechnology, Inc.

Conditions Healthy

Interventions neratinib

Updated 6 times since 2017 Last updated: May 10, 2012 Started: Mar 31, 2008 Primary completion: Apr 30, 2008 Completion: Apr 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy and is currently completed. Puma Biotechnology, Inc. leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Puma Biotechnology, Inc.

Data source: Puma Biotechnology, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.